| Schedule of Segment Reporting Information, by Segment |
Segment information is presented below showing revenue, significant expenses and net loss (the closest GAAP measure to Adjusted EBITDA), in the same manner that the CODM reviews the operating results in assessing performance and allocating resources. | | | | | | | | | | | | | | | | | | | | | | | | | Twelve Months Ended December 31, | | ($ in thousands) | | | | | 2025 | | 2024 | | 2023 | | Revenue | | | | | $ | 151,818 | | | $ | 180,350 | | | $ | 195,917 | | | Operating expenses: | | | | | | | | | | Cost of service (exclusive of depreciation and amortization) (1) | | | | | 61,690 | | | 71,149 | | | 73,773 | | | Advertising cost | | | | | 27,316 | | | 33,429 | | | 25,938 | | | Facility selling, general, and administrative expense | | | | | 21,089 | | | 22,933 | | | 24,694 | | Corporate selling, general, and administrative expense (2) (3) | | | | | 33,775 | | | 42,518 | | | 51,749 | | | | | | | | | | | | | Depreciation and amortization | | | | | 12,781 | | | 11,888 | | | 10,253 | | Loss on impairment of long-lived assets(3) | | | | | 4,575 | | | 16 | | | (212) | | Cost related to closing facility, net (4) | | | | | 2,152 | | | — | | | — | | | Total operating expenses | | | | | 163,378 | | | 181,933 | | | 186,195 | | | Loss from operations | | | | | (11,560) | | | (1,583) | | | 9,722 | | | Interest expense, net | | | | | 6,078 | | | 6,247 | | | 6,485 | | | Pre-tax net loss | | | | | (17,638) | | | (7,830) | | | 3,237 | | | Income tax (benefit)/expense | | | | | (5,971) | | | 188 | | | 7,477 | | | Net loss | | | | | $ | (11,667) | | | $ | (8,018) | | | $ | (4,240) | | | | | | | | | | | | | Segment assets | | | | | $ | 187,304 | | | $ | 209,996 | | | $ | 204,891 | |
| | | | | | | (1) | Cost of services includes the costs of physicians, nursing, supplies and rent directly related to the performance of procedures at the facility level. | | (2) | During the first quarter of fiscal year 2024, the Company recorded a cumulative reversal of stock compensation expense of $10.4 million related to reassessing the probability of achieving the performance target on certain of the Company's performance-based stock units. See Note 6 to the consolidated financial statements included in this Annual Report on Form 10-K for further discussion. | | (3) | During the fiscal year ended 2025, the Company recorded a $4.5 million loss related to the impairment of a portion of the Salesforce implementation project and $0.1 million related to the corporate office PPE write-off. See Note 1 to the consolidated financial statements included in this Annual Report on Form 10-K for further discussion. | | (4) | During the fiscal year ended 2025, the Company recorded $2.2 million in costs related to the closure of the London facility. Comprising of that amount is a $2.4 million loss on London PPE, $3.3 million rent expense from accelerated amortization, offset by a $3.2 million gain on the deconsolidation as of December 31, 2025 related to net liabilities and $0.3 million income from reclassification of CTA. |
|